June 1, 2008

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

.   .   

Related Articles:

Internal Medicine for Nephrologists

Comments are closed.